Coral Laboratories Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 8, 2025, 5:11 am

Competitors of Coral Laboratories Ltd

All Competitor Stocks of Coral Laboratories Ltd

Quarterly Result

Last Updated: August 19, 2025, 8:45 pm

Below is a detailed analysis of the quarterly data for Coral Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 18.82 Cr.. The value appears to be declining and may need further review. It has decreased from 28.13 Cr. (Mar 2025) to 18.82 Cr., marking a decrease of 9.31 Cr..
• For Expenses, as of Jun 2025, the value is 16.64 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 25.44 Cr. (Mar 2025) to 16.64 Cr., marking a decrease of 8.80 Cr..
• For Operating Profit, as of Jun 2025, the value is 2.18 Cr.. The value appears to be declining and may need further review. It has decreased from 2.69 Cr. (Mar 2025) to 2.18 Cr., marking a decrease of 0.51 Cr..
• For OPM %, as of Jun 2025, the value is 11.58%. The value appears strong and on an upward trend. It has increased from 9.56% (Mar 2025) to 11.58%, marking an increase of 2.02%.
• For Other Income, as of Jun 2025, the value is 2.05 Cr.. The value appears strong and on an upward trend. It has increased from 1.71 Cr. (Mar 2025) to 2.05 Cr., marking an increase of 0.34 Cr..
• For Interest, as of Jun 2025, the value is 0.06 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.04 Cr. (Mar 2025) to 0.06 Cr., marking an increase of 0.02 Cr..
• For Depreciation, as of Jun 2025, the value is 0.45 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.51 Cr. (Mar 2025) to 0.45 Cr., marking a decrease of 0.06 Cr..
• For Profit before tax, as of Jun 2025, the value is 3.72 Cr.. The value appears to be declining and may need further review. It has decreased from 3.85 Cr. (Mar 2025) to 3.72 Cr., marking a decrease of 0.13 Cr..
• For Tax %, as of Jun 2025, the value is 31.18%. The value appears to be increasing, which may not be favorable. It has increased from 26.49% (Mar 2025) to 31.18%, marking an increase of 4.69%.
• For Net Profit, as of Jun 2025, the value is 2.56 Cr.. The value appears to be declining and may need further review. It has decreased from 2.83 Cr. (Mar 2025) to 2.56 Cr., marking a decrease of 0.27 Cr..
• For EPS in Rs, as of Jun 2025, the value is 7.17. The value appears to be declining and may need further review. It has decreased from 7.92 (Mar 2025) to 7.17, marking a decrease of 0.75.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 3:35 am

Growth

Last Updated: September 5, 2025, 3:01 pm

Balance Sheet

Last Updated: July 25, 2025, 1:31 pm

Below is a detailed analysis of the balance sheet data for Coral Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 4.00 Cr..
• For Reserves, as of Mar 2025, the value is 198.00 Cr.. The value appears strong and on an upward trend. It has increased from 174.00 Cr. (Mar 2024) to 198.00 Cr., marking an increase of 24.00 Cr..
• For Borrowings, as of Mar 2025, the value is 4.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 0.00 Cr. (Mar 2024) to 4.00 Cr., marking an increase of 4.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 25.00 Cr.. The value appears to be improving (decreasing). It has decreased from 28.00 Cr. (Mar 2024) to 25.00 Cr., marking a decrease of 3.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 229.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 206.00 Cr. (Mar 2024) to 229.00 Cr., marking an increase of 23.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 23.00 Cr.. The value appears to be declining and may need further review. It has decreased from 24.00 Cr. (Mar 2024) to 23.00 Cr., marking a decrease of 1.00 Cr..
• For CWIP, as of Mar 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to 2.00 Cr., marking an increase of 2.00 Cr..
• For Investments, as of Mar 2025, the value is 52.00 Cr.. The value appears strong and on an upward trend. It has increased from 50.00 Cr. (Mar 2024) to 52.00 Cr., marking an increase of 2.00 Cr..
• For Other Assets, as of Mar 2025, the value is 152.00 Cr.. The value appears strong and on an upward trend. It has increased from 132.00 Cr. (Mar 2024) to 152.00 Cr., marking an increase of 20.00 Cr..
• For Total Assets, as of Mar 2025, the value is 229.00 Cr.. The value appears strong and on an upward trend. It has increased from 206.00 Cr. (Mar 2024) to 229.00 Cr., marking an increase of 23.00 Cr..

Notably, the Reserves (198.00 Cr.) exceed the Borrowings (4.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Coral Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 67.61. This value is within the healthy range. It has increased from 44.19 (Mar 24) to 67.61, marking an increase of 23.42.
• For Diluted EPS (Rs.), as of Mar 25, the value is 67.61. This value is within the healthy range. It has increased from 44.19 (Mar 24) to 67.61, marking an increase of 23.42.
• For Cash EPS (Rs.), as of Mar 25, the value is 73.24. This value is within the healthy range. It has increased from 49.72 (Mar 24) to 73.24, marking an increase of 23.52.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 563.19. It has increased from 496.83 (Mar 24) to 563.19, marking an increase of 66.36.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 563.19. It has increased from 496.83 (Mar 24) to 563.19, marking an increase of 66.36.
• For Dividend / Share (Rs.), as of Mar 25, the value is 1.50. This value is within the healthy range. It has decreased from 2.00 (Mar 24) to 1.50, marking a decrease of 0.50.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 321.91. It has increased from 234.17 (Mar 24) to 321.91, marking an increase of 87.74.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 98.94. This value is within the healthy range. It has increased from 64.02 (Mar 24) to 98.94, marking an increase of 34.92.
• For PBIT / Share (Rs.), as of Mar 25, the value is 93.31. This value is within the healthy range. It has increased from 58.49 (Mar 24) to 93.31, marking an increase of 34.82.
• For PBT / Share (Rs.), as of Mar 25, the value is 90.89. This value is within the healthy range. It has increased from 58.03 (Mar 24) to 90.89, marking an increase of 32.86.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 67.61. This value is within the healthy range. It has increased from 44.19 (Mar 24) to 67.61, marking an increase of 23.42.
• For PBDIT Margin (%), as of Mar 25, the value is 30.73. This value is within the healthy range. It has increased from 27.33 (Mar 24) to 30.73, marking an increase of 3.40.
• For PBIT Margin (%), as of Mar 25, the value is 28.98. This value exceeds the healthy maximum of 20. It has increased from 24.97 (Mar 24) to 28.98, marking an increase of 4.01.
• For PBT Margin (%), as of Mar 25, the value is 28.23. This value is within the healthy range. It has increased from 24.78 (Mar 24) to 28.23, marking an increase of 3.45.
• For Net Profit Margin (%), as of Mar 25, the value is 21.00. This value exceeds the healthy maximum of 10. It has increased from 18.87 (Mar 24) to 21.00, marking an increase of 2.13.
• For Return on Networth / Equity (%), as of Mar 25, the value is 12.00. This value is below the healthy minimum of 15. It has increased from 8.89 (Mar 24) to 12.00, marking an increase of 3.11.
• For Return on Capital Employeed (%), as of Mar 25, the value is 16.30. This value is within the healthy range. It has increased from 11.55 (Mar 24) to 16.30, marking an increase of 4.75.
• For Return On Assets (%), as of Mar 25, the value is 10.52. This value is within the healthy range. It has increased from 7.67 (Mar 24) to 10.52, marking an increase of 2.85.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.52. It has increased from 0.44 (Mar 24) to 0.52, marking an increase of 0.08.
• For Current Ratio (X), as of Mar 25, the value is 7.07. This value exceeds the healthy maximum of 3. It has increased from 6.18 (Mar 24) to 7.07, marking an increase of 0.89.
• For Quick Ratio (X), as of Mar 25, the value is 6.68. This value exceeds the healthy maximum of 2. It has increased from 5.57 (Mar 24) to 6.68, marking an increase of 1.11.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.85. This value is below the healthy minimum of 4. It has increased from 2.87 (Mar 24) to 3.85, marking an increase of 0.98.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 362.17. This value is within the healthy range. It has decreased from 114,356.50 (Mar 24) to 362.17, marking a decrease of 113,994.33.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 256.38. This value is within the healthy range. It has decreased from 79,763.50 (Mar 24) to 256.38, marking a decrease of 79,507.12.
• For Enterprise Value (Cr.), as of Mar 25, the value is 174.27. It has increased from 71.40 (Mar 24) to 174.27, marking an increase of 102.87.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.52. This value is within the healthy range. It has increased from 0.85 (Mar 24) to 1.52, marking an increase of 0.67.
• For EV / EBITDA (X), as of Mar 25, the value is 4.93. This value is below the healthy minimum of 5. It has increased from 3.12 (Mar 24) to 4.93, marking an increase of 1.81.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.18. This value is within the healthy range. It has increased from 1.59 (Mar 24) to 2.18, marking an increase of 0.59.
• For Price / BV (X), as of Mar 25, the value is 1.25. This value is within the healthy range. It has increased from 0.74 (Mar 24) to 1.25, marking an increase of 0.51.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.18. This value is within the healthy range. It has increased from 1.59 (Mar 24) to 2.18, marking an increase of 0.59.
• For EarningsYield, as of Mar 25, the value is 0.09. This value is below the healthy minimum of 5. It has decreased from 0.11 (Mar 24) to 0.09, marking a decrease of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness